clinical trial · NCT06044493
MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients
Kidney TransplantMyreptic-N TabletMycophenolate mofetil Tablet/Capsule
brief summary
The purpose of this study is to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients after Kidney Transplant Recipients
started
Nov 14, 2023
primary completion
Oct 29, 2025
completion
Oct 29, 2025
last updated
Apr 15, 2026
detailed description
This study is a multi-center, Randomized, Open-label and phase IV clinical trial that evaluates the efficacy and safety of MYREPTIC-N® or MY-REPT® administration for 24 weeks in renal transplant patients combined Calcineurin inhibitor.
official title
A Multicenter, Randomization, Open-label Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol